Dayforce (
DAY), a biotech company, has experienced substantial market activity in recent months. Following an
adjustment of its
target price to $65 by Jefferies, further analysis pointed to an 18.81% potential upside potential. The company also attracted attention when Rimini Street expanded its HCM solutions with the addition of Dayforce's new management service. Later, Hubexo selected Dayforce for its
workforce transformation. Despite this positive news, some sources recommended not investing in DAY due to a perceived lack of compelling reasons to do so. In the first quarter earnings, Dayforce displayed variations in its key metrics against estimates. Despite surpassing Q1 earnings and revenue estimates, it led S&P decliners as profit and Q2 outlook fell.
Analysts insights pointed to a focus on key performance measures in the upcoming Q1 earnings. DAY's conservative accounting was suggested as a potential factor explaining its soft earnings. Despite some setbacks, DAY secured a significant HCM deal and is welcomed to Microsoft Azure Marketplace, indicating they are making strides in their sector. On the downside,
revenue guidance fell short of expectations, leading some sources to label its stock
overvalued.
Dayforce DAY News Analytics from Wed, 31 Jul 2019 07:00:00 GMT to Fri, 23 May 2025 22:56:15 GMT -
Rating 4
- Innovation 3
- Information 3
- Rumor -2
